59 results about "Pancreatic ductal adenocarcinoma" patented technology

The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.

The present invention relates to diagnostic, prognostic and clinical methods of distinguishing high-risk IPMN from more benign IPMN as well as high-grade PanIN and PDAC from low-grade PanIN with moderate sensitivity and very high specificity using Das-1 and related antibodies.

The present invention provides biomarker compositions and methods for the diagnosis and prognosis of PDAC. In a particular embodiment, the invention provides methods and compositions for screening, diagnosis and prognosis of early stage, asymptomatic PDAC.

Compositions and methods for treating solid tumors such as pancreatic ductal adenocarcinoma (PDA) via interfering with the Dectin-1 signaling pathway, for example, using Dectin-1 or Galectin-9 inhibitors.

The present disclosure relates to the identification of genes and gene combinations that are correlated with patients having or being predisposed to developing pancreatic ductal adenocarcinoma (PDAC). In some instances, methods herein utilize panels of 5 or 10 genes to accurately diagnose PDAC, determine the likelihood of developing PDAC, or determine the severity/stages of PDAC. These panels may be used in a molecular diagnostic test.

The invention discloses a pancreatic duct adenocarcinoma related tumor marker LINC01133, and application of a kit for detecting expression level of LINC01133 in the detection and diagnosis of pancreatic duct adenocarcinoma or patient prognostic evaluation. The expression level of LINC01133 is closely related to the clinical pathological parameters of pancreatic duct adenocarcinoma and the patientprognosis, and can be adopted as a specific tumor marker in pancreatic duct adenocarcinoma detection and a prognostic indicator, and thus is of an important clinical value.

The invention discloses a method for constructing a pancreatic cancer cell line by positive expression of Chinese B7-H5. The method comprises the following steps of 1, collecting of a specimen; 2, preparing of an Organoid type organ complete culture medium; 3, digestion of tissues; 4, constructing and culture of Organoid type organs of pancreatic cancer; 5, cell generation pass and culture. The method has the beneficial effects that the biology features of the constructed Chinese pancreatic cancer cell line sipanc-1076 are used as pancreatic ductal adenocarcinoma; the particular characteristicof positive expression of B7-H15 which does not exist in other commercialized human pancreatic cancer cell lines is realized; the tumor forming property is good; the method can be applied to the study on tumor immune escape of pancreatic cancer, analysis of related genealogy of Chinese pancreatic cancer, and the like.

The invention discloses application of crude extract of radix tetrastigme to preparation of a chemotherapeutic medicament for inhibiting the pancreatic cancer. The invention further discloses a medicament for inhibiting the pancreatic cancer. The medicament comprises one or more of four components as follows: a component-1 (10% (1-2) EtOH extract), a component-2 (10% (-3) to 30%(1-2) EtOH extract), a component-3(30%(-1) to 50%(-1) EtOH extract) and a component-4 (50%(-2) to 95%(-2) EtOH extract). The invention further discloses application of the crude extract of the radix tetrastigme in the aspect of inhibiting the pancreatic cancer. The application comprises the following process of: respectively implanting four types of pancreatic ductal adenocarcinoma (PDAC) cells into a 96-hole plate;carrying out cell adherence, and respectively adding four components of the crude extract of the radix tetrastigme; carrying out shooting under a fluorescence microscope; and measuring a cell survival rate by CCK-8. The invention additionally further provides a method for acquiring the crude extract of the radix tetrastigme. Application of the radix tetrastigme, which is disclosed by the invention, provides a new treatment target for the chemotherapeutic medicament and a treatment medicament for the pancreatic cancer.

This invention relates to a novel approach for the identification and stratification of subtypes of cancer, particularly pancreatic ductal adenocarcinoma (PDAC). The invention furthermore relates to a novel approach with respect to the treatment of cancer, particularly pancreatic ductal adenocarcinoma (PDAC).

The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.

This invention relates to novel approaches for the identification and stratification of subtypes of pancreatic ductal adenocarcinoma (PDAC), in particular to novel PDAC subtype-specific markers, and to diagnostic kits comprising reagents for detecting said markers.

The invention discloses a Chinese pancreas cancer cell line sipanc-187 establishment method. The method includes the following steps: 1. specimen acquisition; 2. tissue digestion; 3. PDX nude mouse tumor-bearing; and 4. tumor cell culture and passage. The beneficial effects of the invention are that a Chinese pancreas cancer cell line sipanc-187 established according to the invention is biologically characterized by pancreatic ductal adenocarcinoma, wherein the Chinese pancreas cancer cell line sipanc-187 has good tumorigenicity and certain medicine resistance. The Chinese pancreas cancer cellline sipanc-187 can be greatly applied to research of pancreas cancer tumors and a chemotherapy medicine-resistance mechanism, pedigree analysis of Chinese pancreas cancer related genes, and the like.

The application relates to methods based on modulating mammalian intestinal and/or pancreatic microbiota and related probiotic, prebiotic, and anti-bacterial compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.